Trial Profile
An Open-label, Multicenter, Pharmacokinetic Study of a FimH Blocker, EB8018, in Crohn's Disease Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs Sibofimloc (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics; Proof of concept
- Sponsors Enterome
- 09 Mar 2022 Results published in the Journal of Gastroenterology and Hepatology
- 01 Feb 2021 Status changed from active, no longer recruiting to completed.
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020